http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2596630-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e5a537a96be1772993d33122a388df7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b74695f4c6259a8598b722c1ef6eefa http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec57e6016f54b2b28b86215c2066e8d1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554 |
| filingDate | 2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e4fa38259be0abe6e5b970aa06352a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e77f76121309ef4b0b3752cc3dab408d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29138eff3de9294c21b24e28bb6902c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c732eda69d282d7f9c0a70cc457cd18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46a401f82f6b68b9699f1edc19b00725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b81df5c87503bcbe49a2bf1ca5973f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6930f93e80488debca59735d55d1be6e |
| publicationDate | 2018-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2596630-B1 |
| titleOfInvention | 5-arylpyrid [2,3-e] [1,4] thiazepinone derivatives with mitochondrial sodium / calcium exchanger blocking activity |
| abstract | 5-arylpyrid [2,3-e] [1,4] thiazepinone derivatives with mitochondrial sodium / calcium exchanger blocking activity. # {IMAGE-01} # The present invention relates to compounds of general formula (I), and its use in the manufacture of useful medicines for the treatment of neurodegenerative diseases, stroke, epilepsy, diabetes or, in general, any disease or pathology caused by altered biological functions where the mitochondrial sodium / calcium exchanger is involved. These diseases have been described as having mitochondrial dysfunction and an alteration of homeostasis of Ca {sup, 2 +} in neurons. Therefore, the compounds of the general formula (I) have the Na {sup, +} / Ca {sup, 2 +} exchanger of the mitochondria as biological targets. In addition, given the lack of potent and selective pharmacological tools to study the Na {sup, +} / Ca {sup, 2 +} exchanger of mitochondria, the compounds of the invention are useful for studying the physiology and pathophysiology of this target. biological in processes where its role has been discovered, or in future experimental observations. The present invention can be framed in the field of the pharmaceutical industry. |
| priorityDate | 2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 189.